The selective interaction of lixisenatide leads to an increase in intracellular cAMP and stimulates glucose‑dependent insulin secretion from pancreatic b‑cells, simultaneously decreasing glucagon secretion from a‑cells. Lixisenatide slows gastric emptying, thus improving postprandial glucose control.